Synthetic Route Optimization of PF-00868554, An HCV Polymerase Inhibitor in Clinical Evaluation

[摘要]：This paper describes the optimization efforts to establish an enabling synthesis to provide multigram quantity of PF-00868554, an HCV polymerase inhibitor currently in phase II clinical evaluations.

[全文传递流程]：

一般上传文献全文的时限在1个工作日内